MedicGo
Failure of somatostatin to affect human chorionic somatomammotropin and human chorionic gonadotropin secretion in vitro.
Metadata
Journaljournal of clinical endocrinology & metabolism5.399Date
1978-Nov
Type
Research Support, U.S. Gov't, P.H.S.
Journal Article
Volume
1978-Nov / 47 : 1141-3
Author
Macaron C , Kyncl M , Rutsky L , Halpern B , Brewer J
DoiPMIDMESH
Bucladesine
Cell Line
Choriocarcinoma
Chorionic Gonadotropin
Female
Humans
Organ Culture Techniques
Placenta
Placental Lactogen
Pregnancy
Somatostatin
Uterine Neoplasms
Abstract
The effect of somatostatin (SRIF) on human chorionic somatomammotropin (hCS) secretion was studied in human placental explants cultured in vitro. In the experimental flasks, SRIF was added in a concentration of 10, 100, and 1000 ng/ml media; hCS levels measured by RIA were not different from those found in the control flasks. In separate experiments, we investigated the action of SRIF on hCG secretion by a human malignant choriocarcinoma cell line maintained in tissue culture. SRIF (1000 ng/ml) did not inhibit basal or dibutyryl cAMP-induced stimulation of hCG secretion. These results suggest that somatostatin does not suppress hCS or hCG release in vitro from normal or malignant trophoblast, respectively.
Fav
Like
Download
Share
Export
Cite
5.4
J Clin Endocrinol Metabjournal of clinical endocrinology & metabolism
Metadata
LocationUnited States
FromENDOCRINE SOC

No Data

© 2017 - 2020 Medicgo
Powered by some medical students